Schonfeld Strategic Advisors’s Benitec Biopharma BNTC Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.63M	Sell	153,179 -109,026	-42%	-$1.26M	0.01%	902
2025 Q4	$3.53M	Buy	262,205 +1,786	+0.7%	+$24.7K	0.02%	673
2025 Q3	$3.65M	Buy	260,419 +2	+0%	+$26	0.02%	737
2025 Q2	$3.05M	Sell	260,417 -1,347	-0.5%	-$18.8K	0.02%	776
2025 Q1	$3.41M	Buy	261,764 +1,347	+0.5%	+$16.3K	0.02%	678
2024 Q4	$3.29M	Sell	260,417 -12,400	-5%	-$134K	0.02%	637
2024 Q3	$2.51M	Buy	272,817 +12,400	+5%	+$111K	0.02%	790
2024 Q2	$1.82M	Buy	+260,417	New	+$1.92M	0.01%	945

Other funds holding BNTC

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Schonfeld Strategic Advisors's BNTC Position: Q1 2026 in Review

Schonfeld Strategic Advisors reduced its Benitec Biopharma (BNTC) stake by 42% in Q1 2026, selling an estimated $1.26M and leaving 153,179 shares worth $1.63M. The position accounts for 0.01% of the portfolio, ranked #902.

Schonfeld Strategic Advisors first reported a position in BNTC in Q2 2024 and has held it in 8 quarters since. The position peaked at $3.65M in Q3 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.

Schonfeld Strategic Advisors held 153,179 shares of Benitec Biopharma worth $1.63M as of Q1 2026.
Schonfeld Strategic Advisors sold 109,026 Benitec Biopharma shares in Q1 2026, an estimated $1.26M.
Benitec Biopharma made up 0.01% of Schonfeld Strategic Advisors's portfolio in Q1 2026, its #902 holding.
Schonfeld Strategic Advisors first reported a position in Benitec Biopharma in Q2 2024 and has held it in 8 quarters since.
Schonfeld Strategic Advisors's Benitec Biopharma position peaked at $3.65M in Q3 2025.
88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.